Gilead Sciences, Inc. (GILD): Price and Financial Metrics

Gilead Sciences, Inc. (GILD)

Today's Latest Price: $67.38 USD

4.05 (6.40%)

Updated Jan 19 11:58am

Add GILD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

GILD Stock Summary

  • GILD has a market capitalization of $79,385,937,676 -- more than approximately 97.23% of US stocks.
  • With a price/earnings ratio of 62.61, Gilead Sciences Inc P/E ratio is greater than that of about 83.33% of stocks in our set with positive earnings.
  • Of note is the ratio of Gilead Sciences Inc's sales and general administrative expense to its total operating expenses; only 15.87% of US stocks have a lower such ratio.
  • Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are ATVI, BDX, ZTS, NTES, and ADI.
  • GILD's SEC filings can be seen here. And to visit Gilead Sciences Inc's official web site, go to

GILD Stock Price Chart Interactive Chart >

Price chart for GILD

GILD Price/Volume Stats

Current price $67.38 52-week high $85.97
Prev. close $63.33 52-week low $56.56
Day low $64.60 Volume 10,358,503
Day high $68.15 Avg. volume 10,380,159
50-day MA $60.28 Dividend yield 4.29%
200-day MA $68.33 Market Cap 84.46B

Gilead Sciences, Inc. (GILD) Company Bio

Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

GILD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$67.38$27.71 -56%

We started the process of determining a valid price forecast for Gilead Sciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Gilead Sciences Inc ranked in the 33th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 56%. The most interesting components of our discounted cash flow analysis for Gilead Sciences Inc ended up being:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 73. Its equity weight surpasses that of just 24.78% of free cash flow generating stocks in the Healthcare sector.
  • Its compound free cash flow growth rate, as measured over the past 5.5 years, is -0.12% -- higher than only 12.54% of stocks in our DCF forecasting set.
  • Gilead Sciences Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 14.21% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Gilead Sciences Inc? See BIO, MD, A, BAX, and JNJ.

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about Gilead Sciences Inc that investors may wish to consider to help them evaluate GILD as an investment opportunity.

Alaska Loaded Up on Tesla Stock. Here Are 3 Stocks It Sold.

Alaska’s Department of Revenue dramatically raised its investment in Tesla stock, and reduced investments in Intel, Gilead Sciences, and Qualcomm shares in the fourth quarter.

Yahoo | January 18, 2021

‘Gilead (GILD) Has No Near-Term Growth Drivers’, Says Nelson Roberts Investment Advisors

Nelson Roberts Investment Advisors, an employee-owned investment advisory firm that provides asset and wealth management published its third-quarter 2020 Investor Letter – a copy of which can be downloaded here. The Firm’s focal point and target is to maintain a long term value and growth of assets over time. You can view the fund’s top 10 […]

Yahoo | January 17, 2021

Gilead: The Widow's Walk

Like a captain's wife searching the horizon for far too many anxious mornings, Gilead's (GILD) shareholders have been looking for signs that it has regained a revenue growth trajectory. In this article I will urge that for the first time in a very long time there are indeed causes for...

Out of Ignorance on Seeking Alpha | January 15, 2021

Gilead Sciences (GILD) Presents At 39th Annual JPMorgan Virtual Healthcare Conference - Slideshow

The following slide deck was published by Gilead Sciences, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 15, 2021

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $63.33 in the latest trading session, marking a +1.49% move from the prior day.

Yahoo | January 15, 2021

Read More 'GILD' Stories Here

GILD Price Returns

1-mo 14.05%
3-mo 13.17%
6-mo -8.87%
1-year N/A
3-year -7.23%
5-year -10.99%
YTD 15.65%
2020 -6.70%
2019 7.88%
2018 -9.92%
2017 2.96%
2016 -27.59%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8683 seconds.